Stay updated with breaking news from Alkermes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
JPMorgan Chase & Co. reaffirmed their neutral rating on shares of Alkermes (NASDAQ:ALKS – Free Report) in a report released on Monday morning, Benzinga reports. They currently have a $33.00 target price on the stock. A number of other research analysts also recently issued reports on the stock. TheStreet raised shares of Alkermes from a […]
Environmental Protection & Sustainability at Alkermes
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor...
Rhenman & Partners Asset Management AB grew its position in Alkermes plc (NASDAQ:ALKS – Free Report) by 159.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 350,000 shares of the company’s stock after acquiring an additional 215,000 shares during the quarter. […]
Check out this week’s medical marketing news, people on the move and industry chatter.